Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Download Presentation Slides

702 views

Published on

  • D0WNL0AD FULL ▶ ▶ ▶ ▶ http://1lite.top/KOsnL ◀ ◀ ◀ ◀
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Try this before jerking off. Just send a message and ask to F.U.C.K... ★★★ http://t.cn/AiuWKDWR
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Download Presentation Slides

  1. 1. David E.I. Pyott Chairman & CEO Allergan, Inc. Global Supply Chain – Beyond Logistics Alone
  2. 2. A Global Leader in Specialty Pharmaceuticals and Medical Devices <ul><li>Founded 1950 in Los Angeles </li></ul><ul><li>David Pyott is 3rd CEO in 58 year history </li></ul><ul><ul><li>~ Approximately 8,800 employees </li></ul></ul><ul><ul><li>~ 2008 sales approximately $4.3 billion </li></ul></ul><ul><ul><li>23 sales subsidiaries in No. America, Europe, Asia–Pacific, Latin America </li></ul></ul><ul><ul><li>Market capitalization approx $12 billion*, 8 times increase since 1997 </li></ul></ul>Plants R&D Facilities
  3. 3. High Revenue Growth Driven by Innovation $ in billions * Pharmaceutical only, in local currency excluding divested products 1 Growth in local currency includes Allergan Medical, excluding BOTOX ® Japan 2 Growth in local currency Includes Allergan Medical, EndoArt, and Corneal 21% Compound Annual Sales Growth 1998 - 2007 $0.7 1998* 1999* 2000* 2001* 2002* 2003* 2004* 2005* 2006 2007 +25% +25% +26% +18% +21% +20% +15% +16% +26% 2 $3.9 +34% 1 $3.0 AGN Allergan Medical Allergan Medical +105% (Organic +49%) +14% $2.7 $0.7 $0.8 $1.0 $1.1 $1.4 $1.7 $2.0 $2.3 $2.6 $3.1 1998* 1999* 2000* 2001* 2002* 2003* 2004* 2005* 2006 2007 +25% +25% +26% +18% +21% +20% +15% +16% +26% 2 $3.9 +34% 1 $3.0 $0.4 $0.8 AGN Rx +17% Rx +15% Allergan Medical Allergan Medical +105% (Organic Allergan Medical +105% (Organic AGN Rx +15% YTD Q3 ‘08 Allergan Medical +12% $3.3 $0.6
  4. 4. Strong EPS 1 Growth 1 Adjusted for non-GAAP items and 2002 spin-off of Advanced Medical Optics, Inc. Includes the effect of EITF 04-8. Historical EPS adjusted for Q2 2007 stock split. See reconciliation at end of presentation. 2 Pre IRS Tax Settlement 3 2006 EPS growth excludes FAS 123R stock option expense 21% Compound Annual EPS Growth +25% +22% +20% +20% +27% +18% 3 +19% 2000 2001 2002 2003 2004 2005 2 2006 2007 $0.59 $0.74 $0.94 $1.15 $1.38 $1.65 $1.83 $2.18
  5. 5. Diversified Business Segments * Proforma growth in US $ including Inamed, Corneal, and EndoArt in prior year Breast Aesthetics 8% (+30%) * Obesity Intervention 7% (+54%) * BOTOX ® Cosmetic 16% (+29%) Ophthalmology 45% (+16%) Facial Aesthetics 5% (+102%) * BOTOX ® Therapeutic 16% (+19%) Skin Care 3% (-12%) FY 2007 $3.9 Billion +29%
  6. 6. Global Leader in a Few Selected Medical Specialties Yellow-shaded sections represent areas of interest for licensing and acquisitions <ul><li>Follow R&D technologies into specialties </li></ul><ul><li>Build presence within specialties organically and by acquisitions </li></ul>Ophthalmology <ul><li>Glaucoma </li></ul><ul><li>LUMIGAN ® </li></ul><ul><li>ALPHAGAN ® </li></ul><ul><li>GANFORT™ </li></ul><ul><li>COMBIGAN™ </li></ul><ul><li>IOP lowering </li></ul><ul><ul><li>PG Analog </li></ul></ul><ul><ul><li>Sus. Release </li></ul></ul>Retina - POSURDEX ® - TRIVARIS™ - AGN-745 (siRNA) - Brimo-DDS - TKI Urologics BPH - BOTOX ® Obesity - LAP-BAND ® - BIB™ - EASYBAND™ Neurosciences BOTOX ® Therapeutic - Spasticity, CD, Headache, JCP, etc. Alpha Agonists - Pain <ul><li>GSK Co-promote </li></ul><ul><li>IMITREX ® </li></ul><ul><li>AMERGE ® </li></ul>Medical Dermatology TAZORAC ® Topical - Cream - Gel ACZONE ® - Topical Acne BOTOX ® - Hyperhidrosis * Plastic surgery & dermatology OAB - SANCTURA XR™ - BOTOX ® <ul><li>Dry Eye </li></ul><ul><li>RESTASIS ® </li></ul><ul><li>REFRESH ® </li></ul><ul><li>OPTIVE™ </li></ul><ul><li>Ocular Surface Disease </li></ul><ul><li>ACULAR ® </li></ul><ul><li>ZYMAR ® </li></ul><ul><li>ELESTAT ® </li></ul><ul><li>ALOCRIL ® </li></ul>Medical Aesthetics * <ul><li>Physician </li></ul><ul><li>Dispensed </li></ul><ul><li>Creams </li></ul><ul><li>CLINIQUE MEDICAL </li></ul><ul><li>M.D. FORTE ® </li></ul><ul><li>PREVAGE ® MD </li></ul><ul><li>VIVITÉ ® </li></ul>Breast Aesthetics Dermal Fillers - JUVÉDERM™ - SURGIDERM ® - VOLUMA™ BOTOX ® COSMETIC Bimatoprost - Eyelash Growth Targeted BOTOX ® (Next Generation) - Pain Bladder Cancer - Apaziquone (EOQUIN ® )
  7. 7. R&D Integral to “Supply Chain” 1 Adjusted for non-GAAP items. See reconciliation at end of presentation. (Periods 1998-2001 not restated for 2006 change in financial reporting of amortization of acquired intangible assets) 2 Includes Allergan Medical activities for 9 months. 3 2008E represents midpoint of guidance provided on October 29, 2008 and has not been updated. This presentation does not reaffirm such guidance. 4 Internal analysis of public filings of AGN peer group <ul><li>Investment doubled in 3 years </li></ul><ul><li>Top quartile R&D investment as a % of sales in pharma / medical device 4 </li></ul><ul><li>R&D Network </li></ul><ul><li>Irvine </li></ul><ul><li>London </li></ul><ul><li>Lausanne </li></ul><ul><li>Bangalore </li></ul>2006 2 2007 $98 $135 $164 $188 1 $228 1 $305 1 $343 1 $384 1 $476 1 R&D $ (in millions) R&D as a % of Sales ~$734 $646 1 - 100 200 300 400 500 600 700 800 1998 1999 2000 2001 2002 2003 2004 2005 2008E 3 10.0% 12.0% 14.0% 16.0% 18.0% 20.0% +38% +15% +21% +34% +21% +12% +12% +24% +36% +14%
  8. 8. <ul><li>Highly concentrated manufacturing </li></ul><ul><ul><li>1997 10 plants for $0.6B in sales to 2009 5 plants with ~$4.5B in sales </li></ul></ul><ul><li>1998 - collapsed number of manufacturing plants from 10 to 5 </li></ul><ul><li>2006 - acquired Inamed Corporation, Santa Barbara </li></ul><ul><ul><li>by 2009 moved from 3 plants to 1 </li></ul></ul><ul><ul><li> - acquired Corneal France </li></ul></ul><ul><li>2009 Footprint - 5 plants </li></ul><ul><ul><li>Botox - Global Supply - Ireland </li></ul></ul><ul><ul><li>Dermal Fillers - Global Supply - France </li></ul></ul><ul><ul><li>Breast Implants - Global Supply - Costa Rica </li></ul></ul><ul><ul><li>LAP-BAND - Global Supply - Costa Rica </li></ul></ul><ul><ul><li>Ophthalmic Pharmaceuticals - Texas  N. America </li></ul></ul><ul><ul><li>- Brazil  S. America </li></ul></ul><ul><ul><li>- Ireland  Europe, Africa, Asia Pacific </li></ul></ul>Global Supply Chain Beyond Logistics Alone
  9. 9. <ul><li>Plant concentration </li></ul><ul><ul><li>Driven by </li></ul></ul><ul><ul><li>Capital intensity </li></ul></ul><ul><ul><li>Ever higher Good Manufacturing Practices standards (GMP) </li></ul></ul><ul><ul><li>Good Laboratory Practices standards (GLP) </li></ul></ul><ul><ul><li>Rigorous government inspections requiring specialist skills </li></ul></ul><ul><li>Benefit of Fx diversification </li></ul><ul><ul><li>Dual registrations for product licenses </li></ul></ul><ul><li>Inventory de-risking </li></ul>Global Supply Chain Beyond Logistics Alone
  10. 10. <ul><li>Strategy of focusing on selected medical specialties </li></ul><ul><li>Typically 10,000 physicians in U.S. and equivalent in foreign markets </li></ul><ul><li>Strategic advantage vs “Big Pharma” companies </li></ul><ul><ul><li>Focus of R&D investment and experience </li></ul></ul><ul><ul><li>Typically largest sales force in world </li></ul></ul><ul><li>Global selling and marketing infrastructure </li></ul><ul><ul><li>23 sales subsidiaries </li></ul></ul><ul><ul><li>+ ~70 distributors </li></ul></ul><ul><ul><li>Regional marketing: Irvine, Toronto, Sao Paulo, London, Singapore </li></ul></ul>Global Supply Chain Beyond Logistics Alone
  11. 11. Allergan’s Leading Market Share Positions Product launched 2008 No. 5 3% <ul><li>Urology </li></ul>No. 6 6% <ul><li>Medical Dermatology </li></ul>U.S. Share No. 1 77% <ul><li>Gastric Bands & Balloons </li></ul>No. 2 38% <ul><li>Breast Aesthetics </li></ul>No. 2 30% <ul><li>Dermal Fillers </li></ul>No. 1 85% <ul><li>Botox </li></ul>Fastest Growing Company for 5 years No. 2 16% <ul><li>Ophthalmic Pharmaceuticals </li></ul>Rank Global Share

×